Drug intelligence / Profile preview

fentanyl + isoflurane

Development stage
Unknown
Lead developer
Johnson & Johnson
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
Administration
Intravenous, Inhalation
01

Overview

Fentanyl + isoflurane refers to the concurrent use of two anesthetic agents—fentanyl, a potent synthetic opioid analgesic, and isoflurane, a volatile inhalational general anesthetic. This combination is commonly used in both human and veterinary anesthesia to provide balanced anesthesia with enhanced analgesia and reduced requirements for each agent. Fentanyl acts primarily as a μ-opioid receptor agonist, providing strong analgesia and reducing the minimum alveolar concentration (MAC) of isoflurane required for surgical anesthesia by up to 60–63% at clinically relevant plasma concentrations[1][5]. Isoflurane induces general anesthesia by enhancing inhibitory neurotransmission via GABA-A receptors and other central nervous system targets. The combination allows for lower doses of each drug, potentially minimizing side effects such as cardiovascular depression associated with higher doses of either agent alone[2][4]. However, their combined use can result in significant decreases in heart rate, mean arterial pressure, and cardiac index; careful monitoring during administration is essential[2].

02

Targets

GABRR (GABA-A receptor subunit rho)KCNK2 (Potassium channel subfamily K member 2)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on fentanyl + isoflurane.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on fentanyl + isoflurane.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call